

Customer No. 28880

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT : Gerwyn Bish, et al. EXAMINER :
SERIAL NO. : ART UNIT :
FILED : CONF. NO. :
FOR : PIPERAZINE DERIVATIVES WHICH EXHIBIT ACTIVITY AS
SEROTONIN AND NORADRENALINE RE-UP TAKE INHIBITORS

Statement as Provided by 37 CFR 1.97(b)

Commissioner for Patents
P.O. BOX 1450
Alexandria, VA 22313-1450

Dear Sir:


The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of the first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

It is requested that the references listed on the attached form PTO-SB-08A/08B be included in the "References Cited" portion of any patent issuing from this application (MPEP § 1302.12).

It is understood by the Applicants that this paper requires no fee; however, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Respectfully submitted,

Dated: July 13, 2006



Paul M. Misiak
Registration No. 58,310
Warner-Lambert Company LLC
2800 Plymouth Road
Ann Arbor, MI 48105
Telephone: (734) 622-1435
Facsimile: (734) 622-2928

Confirmation No.

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Complete if Known

Application Number

Filing Date

First Named Inventor

Gerwyn Bish, et al.

Art Unit

Examiner Name

Attorney Docket Number

PC32050A

Sheet

1

of

2

Attorney Docket Number

PC32050A

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner
Signature

/Erich Leeser/

Date _____

Date Considered

01/30/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /EL/

EXPRESS MAIL NO. ED 941899614 US
DOCKET NO. PC32050A

AP20 Rec'd PCT/PTO 13 JUL 2006

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number

10/586029

Filing Date

First Named Inventor

Gerwyn Bish, et al.

Art Unit

Examiner Name

Sheet

2

of

2

Attorney Docket Number

PC32050A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KAGAYAKI NATSUKA ET AL, "Synthesis and Structure-Activity Relationship of 1-Substituted 4-(1,2-Diphenylethyl)Piperazine Derivatives having Narcotic Agonists and Antagonist Activity", Journal of Medicinal Chemistry, Am.Chem Soc., (1987), pp 1779-1787, Vol. 30	
		BOLLI, M.H. ET AL, "Development of a polymer bound Wittig reation and use in multi-step organic synthesis for the overall conversion of alcohols to beta-hydroxyamines", J. Chem Soc, (1998), pp. 2243-2246	
		SHIMOKAWA, N. ET AL., "Studies on analgesic agents. 1. Preparation of 1,2--diphenyl-2-(4-substitued-1-piperaziny 1)ethanol derivatives and structure-activity relationship", J. Med. Chem, (1979), pp 58-63, Vol. 22	
		NATSUKA. K. ET AL, "Studies on 1-Substituted 4-(1,2-Diphenylethyl)Piperazine Derivatives and their Analgesic Activities", J. Med. Chem., (1975), pp 1240-1244, Vol. 18	
		Database Crossfire Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt-Main, De; Database accession no. BRN: 561221, Abstract	
		ARTIGAS, F. , "Selective Serotonin/Noradrenaline reuptake Inhibitors (SNRIS) Pharmacology and Therapeutic Potential in the Treatment of Depressive Disorders", CNS Drugs, (1995), pp 70-89, Vol. 4	

Examiner
Signature

/Erich Leeser/

Date

Considered

01/30/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /EL/